Clearside Biomedical Inc CLSD

NAS: CLSD | ISIN: US1850631045   30/04/2025
0,865 USD (+2,44%)
(+2,44%)   30/04/2025

28 maart 2022 · Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis · Persbericht

25 oktober 2021 · Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis · Persbericht

16 augustus 2021 · Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India · Persbericht

2 juni 2021 · Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) · Persbericht

10 maart 2021 · Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update · Persbericht

2 maart 2021 · Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD · Persbericht

24 februari 2021 · Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021 · Persbericht

23 februari 2021 · Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 · Persbericht

16 februari 2021 · Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program · Persbericht

8 februari 2021 · Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting · Persbericht

12 januari 2021 · Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD · Persbericht

6 januari 2021 · Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering · Persbericht

Mijn selecties